diphenyleneiodonium has been researched along with Idiopathic Parkinson Disease in 2 studies
diphenyleneiodonium: structure in first source; NADPH oxidase inhibitor
dibenziodolium : An organic cation that is fluorene in which the methylene group is replaced by a positively charged iodine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Q | 1 |
| Qian, L | 1 |
| Chen, SH | 1 |
| Chu, CH | 1 |
| Wilson, B | 2 |
| Oyarzabal, E | 1 |
| Ali, S | 1 |
| Robinson, B | 1 |
| Rao, D | 1 |
| Hong, JS | 2 |
| Gao, HM | 1 |
| Zhang, F | 1 |
| Zhou, H | 1 |
| Kam, W | 1 |
2 other studies available for diphenyleneiodonium and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models.
Topics: Animals; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Enzyme Inhibitors; Mice, | 2015 |
Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Amidines; Animals; Animals, Genetically Modified; Benzylamines; Disease Models, Ani | 2011 |